August 18, 2021
InSysBio announces its participation in PAGE 2021 Online meeting which is to be held on the 2nd, 3rd, 6th, and 7th of September 2021. InSysBio team is going to present its latest development at the Virtual Exhibition e-booth and six posters, namely:
Poster session 1.
Friday, Sep 3, 2021,
12:00 PM - 1:00 PM
I-16 "Virtual Patient Populations: Comparison of Approaches in Application to QSP Model Of Erythropoiesis" by Galina Kolesova, Oleg Demin, Alexander Stepanov
I-35 "Prediction of PD-L1 receptor occupancy in the tumor with PBPK/RO model of PD-L1 inhibitors" by Antonina Nikitich, Oleg Demin Jr
I-46 "Quantitative systems pharmacology model of axonal degeneration markers in Alzheimer’s disease" by Tatiana Karelina, Polina Pchelintseva
I-78 "HetaProject – a Single Open Source Platform for Modeling, Simulation and Parameters Estimation in QSP" by Ivan Borisov, Evgeny Metelkin
I-80 "CYTOCON DB as storage of unified data on in vivo human concentrations of cells and molecules in health and disease" by Ekaterina Mogilevskaya, Vlad Leonov, Elita Gerasimuk, Nikolay Pervushin, Nail Gizzatkulov, Oleg Demin
Poster session 2.
Monday, Sep 6, 2021,
12:00 PM - 1:00 PM
Visit our booth and follow our presenters!
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | December 2019 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
1.
03 Dec 2019 15:35
InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting
QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
|
4
|
5
|
6
|
7
|
8
|
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
| |||||
Thank you for your message! We will get back to you shortly.
